Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Marker Therapeutics (MRKR) revenue and earnings history
Marker Therapeutics reported revenue of $3.55M for fiscal 2025 (year ended Dec 31, 2025), −46.2% on the year before, and net income of −$12.2M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +44.8% a year.
What was Marker Therapeutics's revenue in fiscal 2025?
$3.55M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 18, 2026. That is −46.2% on fiscal 2024 ($6.59M).
How fast has Marker Therapeutics's revenue grown?
From $183K in fiscal 2017 to $3.55M in fiscal 2025: a compound annual growth rate of +44.8% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Marker Therapeutics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Marker Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
“—” means the company did not tag that line that year in the standard US taxonomy (some used a tag of their own), not zero. Free cash flow is operating cash flow minus capital expenditure. Buybacks and dividends are the cash paid out in the year, from the cash-flow statement. The report link opens the filing the year’s figures were last stated in.
It reported a net loss in 26 of the years shown (2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$672K in fiscal 2001.
How much cash has Marker Therapeutics returned to shareholders?
Its cash-flow statements show $382K on buying back its own shares over 2 fiscal years ($0 in fiscal 2025). These are the dollar amounts paid in each year, as filed; a year with no figure means none was tagged.
Why is earnings per share not in this table?
Each year's figure here comes from the newest annual report that states it. After a stock split, earlier reports and later reports state per-share figures on different share counts, so a column of EPS would mix the two. Net income is not affected by splits.